These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26739060)

  • 1. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
    Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth.
    Jia X; Wang W; Xu Z; Wang S; Wang T; Wang M; Wu M
    Sci Rep; 2016 Jun; 6():27985. PubMed ID: 27301650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
    Wang S; Zhou R; Sun F; Li R; Wang M; Wu M
    Cancer Lett; 2017 Nov; 409():125-136. PubMed ID: 28923397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth.
    Ding XY; Ding J; Wu K; Wen W; Liu C; Yan HX; Chen C; Wang S; Tang H; Gao CK; Guo LN; Cao D; Li Z; Feng GS; Wang HY; Xu ZF
    Oncogene; 2012 Jun; 31(23):2899-906. PubMed ID: 22002304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
    Jenkins DW; Ross S; Veldman-Jones M; Foltz IN; Clavette BC; Manchulenko K; Eberlein C; Kendrew J; Petteruti P; Cho S; Damschroder M; Peng L; Baker D; Smith NR; Weir HM; Blakey DC; Bedian V; Barry ST
    Mol Cancer Ther; 2012 Aug; 11(8):1650-60. PubMed ID: 22679110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
    Hoey T; Yen WC; Axelrod F; Basi J; Donigian L; Dylla S; Fitch-Bruhns M; Lazetic S; Park IK; Sato A; Satyal S; Wang X; Clarke MF; Lewicki J; Gurney A
    Cell Stem Cell; 2009 Aug; 5(2):168-77. PubMed ID: 19664991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
    Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
    Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
    Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
    Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
    MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells.
    Sharma A; Paranjape AN; Rangarajan A; Dighe RR
    Mol Cancer Ther; 2012 Jan; 11(1):77-86. PubMed ID: 22075160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta-like ligand 4 regulates vascular endothelial growth factor receptor 2-driven luteal angiogenesis through induction of a tip/stalk phenotype in proliferating endothelial cells.
    García-Pascual CM; Zimmermann RC; Ferrero H; Shawber CJ; Kitajewski J; Simón C; Pellicer A; Gómez R
    Fertil Steril; 2013 Dec; 100(6):1768-76.e1. PubMed ID: 24074756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta-like ligand 4-notch blockade and tumor radiation response.
    Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
    J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
    Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
    Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
    BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis.
    Yang MH; Zang YS; Huang H; Chen K; Li B; Sun GY; Zhao XW
    Curr Cancer Drug Targets; 2014; 14(6):557-66. PubMed ID: 25088040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.